Earnings ·
Cytosorbents Corporation reported financial results for the quarter ended June 30, 2026
CTSOCytosorbents Corp
Cytosorbents Corporation reported financial results for the quarter ended June 30, 2026. Revenue was $9.6 million, unchanged from a year ago. Gross margin improved to 73%. Operating loss decreased by 27% to $2.6 million compared to $3.6 million in Q2 2025. Net loss was $4.4 million or $0.07 per share, versus net income of $1.9 million or $0.03 per share in the prior year period, primarily due to non-cash foreign currency translation impacts. Adjusted net loss improved by 22% to $2.8 million or $0.05 per share. Total cash and equivalents were approximately $5.9 million on June 30, 2026. The company operates in the medical technology industry, specializing in blood purification treatments for critical care and cardiac surgery.